July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Preclinical validation of a tissue engineered product consisting in RPE derived from human embryonic stem cells disposed on human amniotic membrane in non-human primates.
Author Affiliations & Notes
  • Christelle Monville
    INSERM/UEVE UMR 861-ISTEM, AFM, Corbeil-Essonnes, France
  • Karim Ben M'Barek
    INSERM/UEVE UMR 861-ISTEM, AFM, Corbeil-Essonnes, France
    CECS/ISTEM, Corbeil-Essonnes, France
  • Stéphane Bertin
    Institut de la Vision, Paris, France
    INSERM U968, Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968; CNRS, UMR_7210, Paris, France
  • Elena Brazhnikova
    Institut de la Vision, Paris, France
    INSERM U968, Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968; CNRS, UMR_7210, Paris, France
  • Habeler Walter
    INSERM/UEVE UMR 861-ISTEM, AFM, Corbeil-Essonnes, France
    CECS/ISTEM, Corbeil-Essonnes, France
  • alexandra Plancheron
    INSERM/UEVE UMR 861-ISTEM, AFM, Corbeil-Essonnes, France
    CECS/ISTEM, Corbeil-Essonnes, France
  • Céline Nouvel-Jaillard
    Institut de la Vision, Paris, France
    INSERM U968, Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968; CNRS, UMR_7210, Paris, France
  • Claire-Maelle Fovet
    MirCen, CEA, Fontenay aux Roses, France
  • Mohamed Jarraya
    Hopital Saint-Louis, APHP, Paris, France
  • Anne-Gaëlle Chartois
    EFS-ABG, Nantes, France
  • Nadège Morand
    Medical Device Engineering, Clermont-Ferrand, France
  • Cyrille Marechal
    Medical Device Engineering, Clermont-Ferrand, France
  • Jose A. Sahel
    Institut de la Vision, Paris, France
    INSERM U968, Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968; CNRS, UMR_7210, Paris, France
  • marc Peschanski
    INSERM/UEVE UMR 861-ISTEM, AFM, Corbeil-Essonnes, France
    CECS/ISTEM, Corbeil-Essonnes, France
  • Olivier Goureau
    Institut de la Vision, Paris, France
    INSERM U968, Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968; CNRS, UMR_7210, Paris, France
  • Footnotes
    Commercial Relationships   Christelle Monville, None; Karim Ben M'Barek, None; Stéphane Bertin, None; Elena Brazhnikova, None; Habeler Walter, None; alexandra Plancheron, None; Céline Nouvel-Jaillard, None; Claire-Maelle Fovet, None; Mohamed Jarraya, None; Anne-Gaëlle Chartois, None; Nadège Morand, Medical Device Engineering (I); Cyrille Marechal, Medical Device Engineering (I); Jose Sahel, Chronocam (I), Chronolife (I), Genesight Biologics (C), Genesight Biologics (I), Genesignal (C), Pixium Vision (C), Pixium Vision (I), Sparing Vision (I), Tilak Healthcare (I); marc Peschanski, None; Olivier Goureau, None
  • Footnotes
    Support  ANR-2010-RFCS005; FRM-DBS20140930777; ANR-10-LABX-65; ANR-11-IDEX-0004-02; Neuratris-ANR-11-INBS-0011; INGESTEM-ANR-11-INBS-000; ANR-10-LABX-73
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5008. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christelle Monville, Karim Ben M'Barek, Stéphane Bertin, Elena Brazhnikova, Habeler Walter, alexandra Plancheron, Céline Nouvel-Jaillard, Claire-Maelle Fovet, Mohamed Jarraya, Anne-Gaëlle Chartois, Nadège Morand, Cyrille Marechal, Jose A. Sahel, marc Peschanski, Olivier Goureau; Preclinical validation of a tissue engineered product consisting in RPE derived from human embryonic stem cells disposed on human amniotic membrane in non-human primates.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5008.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In developed countries, retinal degenerative diseases affecting Retinal Pigmented Epithelium (RPE), including Age-related Macular Dystrophy and inherited retinal diseases such as Retinitis Pigmentosa (RP), are the predominant causes of human blindness worldwide. Despite the scientific advances achieved in the last years, there is no cure for such diseases. In this context, we have developed a cell therapy medicinal product based on our expertise in tissue engineering and in the manipulation of pluripotent stem cells. This novel tissue engineered product (TEP) consists in RPE cells derived from clinical grade human embryonic stem cells disposed on a biocompatible substrate allowing the formation of a 3D functional sheet, suitable for transplantation. After functional validation in a rodent model of RP (Ben M'Barek et al., 2017), our purpose was to test the safety of the surgery and local tolerance in non-human primates (NHP).

Methods : A specific device was developed in order to (i) embed the TEP in gelatin, (ii) allow its transport in a specific medium and (iii) cut the transplant at the right format. Non-human primates (NHP, n=6) were transplanted in one eye (right eye) with the TEP in the macular region. Left eye was left untreated. Retinal integrity and functionality were assessed at different time points (week 1, 2, 4, 6 and 7) through Eye fundus, Optical-coherence tomography (OCT) and electroretinography (ERG). Inflammation was also assessed using slit lamp. At the end of the experimental period, histological analysis was performed to evaluate the correct location and integration of the TEP within the host retina.

Results : We successfully developed a device allowing us to prepare and implant the TEP in the subretinal space of six NHP. We showed that ERG responses were not modified by the surgery and that it did not cause any long lasting inflammation. Moreover, transplanted cells were integrated in the retina and were able to phagocyte photoreceptor debris.

Conclusions : We have shown in NHP that our surgical method of implantation was safe and did not provoke any local inflammation or retinal deterioration. Morphologic and histologic studies indicated that RPE cells were integrated into the host retina and were able to interact with photoreceptors. Our results lay the foundations for clinical studies early 2019.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×